Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim Adbry Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentHarvard Pilgrim Health CarePolicy N/A

    Pharmacy Medical Necessity Guidelines: Adbry (tralokinumab-ldrm)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity coverage for Adbry (tralokinumab-ldrm) for eligible Harvard Pilgrim, Tufts Health Plan Commercial, and Tufts Health Direct members with moderate to severe atopic dermatitis.

    Policy Summary
    PayerHarvard Pilgrim Health Care
    PolicyAdbry (tralokinumab-ldrm) coverage criteria
    Policy CodePolicy N/A
    Change TypeAdministrative update
    Effective DateOctober 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before Adbry is provided to ensure payment eligibility.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12 yearsMinimum patient age
    6 monthsInitial authorization
    12 monthsReauthorization interval
    BSA ≥10%Disease severity threshold
    30 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prerequisite topical therapy

    Coverage Criteria

    Initial Authorization

    Covered when ALL of the following initial authorization criteria are met.

    Initial Authorization Criteria

    • Diagnosis: Documented diagnosis of moderate to severe atopic dermatitis.
    • Disease severity

      • BSA: Body Surface Area is at least 10%.≥10%
      • EASI: Eczema Area and Severity Index score is at least 16.≥16
      • IGA/PGA: Investigator's Global Assessment or Physician Global Assessment score is at least 3.≥3
    • Age: Patient is at least 12 years of age.≥12 years
    • Prescriber: Adbry is prescribed by a dermatologist, allergist, or immunologist.
    • Prior topical therapy: The patient has a documented history of failure of a minimum 30-day supply of one eligible topical therapy, or a 14-day supply for topical corticosteroids, unless contraindicated or clinically significant adverse effects are experienced.30 days; 14 days for topical corticosteroids

      Eligible therapies are medium- or high-potency topical corticosteroids, a calcineurin inhibitor, crisaborole, or ruxolitinib. Document the drug, date, and duration of the trial.

    • Non-duplication: The patient is not receiving Adbry in combination with another biologic drug or a targeted synthetic oral small molecule drug.

    Reauthorization

    Covered for reauthorization when ALL of the following criteria are met.

    Reauthorization Criteria

    • Prior treatment duration: The patient has been receiving Adbry for at least six months.≥6 months
    • Diagnosis: Documented diagnosis of moderate to severe atopic dermatitis.
    • Age: Patient is at least 12 years of age.≥12 years
    • Prescriber:

    Situations Requiring Initial Criteria

    Review under Initial Authorization Criteria in the following circumstances.

    Special review circumstances

    • Less than six months: The patient has received less than six months of therapy.<6 months
    • Restarting therapy: The patient is restarting Adbry.
    • New plan member: The member is new to the plan and stable on Adbry.

    Adbry must not be used in combination with another biologic drug or a targeted synthetic oral small molecule drug. This non-duplication requirement applies to both initial authorization and reauthorization.

    Coding and Clinical Thresholds

    Codesmixed
    No codes listed
    Body Surface Area
    MeasureBody Surface Area (BSA)
    Required thresholdAt least 10%
    Eczema Area and Severity Index
    MeasureEczema Area and Severity Index (EASI)
    Required thresholdAt least 16
    Investigator's Global Assessment/Physician Global Assessment
    Measure

    Provider Actions and Review Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Adbry. Even when another provider obtains the authorization, the provider must ensure that it has been obtained as a condition of payment.

    Step Therapy

    Required Topical Therapy Trial

    Before initial authorization, document failure of at least one eligible topical therapy trial, unless the therapy was contraindicated or caused clinically significant adverse effects.

    • Minimum trial: 30-day supply for medium- or high-potency topical corticosteroids, a calcineurin inhibitor, crisaborole, or ruxolitinib.
    • A 14-day supply is sufficient for topical corticosteroids.

    Policy Background

    Adbry (tralokinumab-ldrm) is an interleukin-13 antagonist indicated for atopic dermatitis. This policy addresses coverage for members with moderate to severe atopic dermatitis who meet the applicable disease-severity, age, specialist-prescriber, prior topical-treatment, and non-duplication requirements.

    Initial coverage requires the patient to be at least 12 years of age and to meet at least one specified severity threshold. Continued coverage requires documented treatment duration, ongoing eligibility, beneficial clinical response, and improvement in at least one atopic dermatitis symptom compared with baseline.

    Initial Authorization Criteria

    Initial Authorization Criteria

    Initial authorization is available when all required clinical, severity, age, prescriber, prior-treatment, and non-duplication criteria are met.

    • Diagnosis: Documented diagnosis of moderate to severe atopic dermatitis.
    • Disease severity

      • BSA: Body Surface Area is at least 10%.≥10%
      • EASI: Eczema Area and Severity Index score is at least 16.≥16

    Reauthorization Criteria

    Reauthorization Criteria

    Reauthorization is available when all continuation requirements are met.

    • Prior treatment duration: The patient has been receiving Adbry for at least six months.≥6 months
    • Diagnosis: Documented diagnosis of moderate to severe atopic dermatitis.
    • Age: Patient is at least 12 years of age.≥12 years

    Required Prerequisite Therapy

    StepRequired prerequisite therapyMinimum trial durationException / documentation
    1
    One of the following: medium- or high-potency topical corticosteroid; calcineurin inhibitor; crisaborole; or ruxolitinib
    30-day supply; 14-day supply for topical corticosteroids
    Document failure of the trial. A contraindication or clinically significant adverse effect may substitute for treatment failure when documented; include the drug, date, and duration of the trial.
    Policy Summary
    PayerHarvard Pilgrim Health Care
    PolicyAdbry (tralokinumab-ldrm) coverage criteria
    Policy CodePolicy N/A
    Change TypeAdministrative update
    Effective DateOctober 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before Adbry is provided to ensure payment eligibility.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Review RisksPolicy BackgroundInitial Authorization CriteriaReauthorization CriteriaRequired Prerequisite Therapy
    Adbry is prescribed by a dermatologist, allergist, or immunologist.
  1. Beneficial clinical response: Compared with baseline, the patient has experienced improvement in at least one of the following: estimated body surface area affected by atopic dermatitis, erythema, induration or thickness, scale of affected areas, or reduction in the use of other topical or systemic therapies.Improvement from baseline in ≥1 measure
  2. Symptom improvement: Compared with baseline, the patient has experienced improvement in at least one symptom of atopic dermatitis, such as pruritus, xerosis, crusting, or lichenification.Improvement from baseline in ≥1 symptom
  3. Non-duplication: The patient is not receiving Adbry in combination with another biologic drug or a targeted synthetic oral small molecule drug.
  4. Investigator's Global Assessment/Physician Global Assessment (IGA/PGA)
    Required thresholdAt least 3
    Patient Age
    RequirementPatient is at least 12 years of age or older
    Applies toInitial authorization criteria
    Topical Therapy Trial
    Required trialMinimum 30-day supply of one eligible topical therapy
    Exception14-day supply for topical corticosteroids
    Eligible therapiesMedium- or high-potency topical corticosteroids, calcineurin inhibitor, crisaborole, or ruxolitinib
    AlternativeA documented contraindication or clinically significant adverse effect may apply
    Documentation Required

    Initial Clinical Documentation

    For initial authorization, document moderate to severe atopic dermatitis, the required disease-severity measure, patient age of at least 12 years, and prescribing by a dermatologist, allergist, or immunologist.

    • Severity must include at least one of: BSA ≥ 10%, EASI ≥ 16, or IGA/PGA ≥ 3.
    Documentation Required

    Topical Therapy History Required

    Document the failed topical therapy and the details of the prerequisite trial before requesting initial authorization.

    • Identify the drug, trial date, and duration.
    • Eligible therapies include medium- or high-potency topical corticosteroids, a calcineurin inhibitor, crisaborole, or ruxolitinib.
    • Document a contraindication or clinically significant adverse effect if the required trial was not completed.
    Documentation Required

    Review Concomitant Targeted Therapy

    Confirm and document that Adbry is not being administered in combination with another biologic drug or a targeted synthetic oral small molecule drug.

    Documentation Required

    Reauthorization Response Documentation

    For reauthorization, document at least six months of Adbry therapy, continued clinical eligibility, and a beneficial response compared with baseline.

    • Document moderate to severe atopic dermatitis, age ≥ 12 years, and prescribing by a dermatologist, allergist, or immunologist.
    • Document improvement in at least one clinical measure, reduction in other topical or systemic therapy use, and improvement in at least one symptom such as pruritus, xerosis, crusting, or lichenification.
    • Confirm Adbry is not being used with another biologic or targeted synthetic oral small molecule drug.
    Denial Risk

    Clinical Eligibility Not Established

    Coverage may be denied when initial clinical eligibility is not established or required documentation is incomplete.

    • Diagnosis of moderate to severe atopic dermatitis must be documented.
    • At least one required severity measure, minimum age of 12 years, and specialist prescribing must be documented.
    • All other initial authorization criteria must also be met.
    Denial Risk

    Required Topical Therapy Trial Missing

    Initial authorization may be denied when the required topical therapy trial is not documented and no contraindication or clinically significant adverse-effect exception applies.

    • Document the failed drug, date, and duration.
    • The required trial is at least 30 days, or 14 days for topical corticosteroids.
    Denial Risk

    Duplicative Targeted Therapy

    Adbry may be denied when it is requested or administered in combination with another biologic drug or a targeted synthetic oral small molecule drug.

    Denial Risk

    Reauthorization Response Criteria Not Met

    Reauthorization may be denied when the patient has not received at least six months of therapy, continued eligibility is not documented, or the required clinical response is not demonstrated.

    • Document improvement from baseline in at least one qualifying clinical measure or reduced use of other topical or systemic therapies.
    • Document improvement from baseline in at least one atopic dermatitis symptom.
    • Confirm continued specialist prescribing, age ≥ 12 years, and absence of duplicative targeted therapy.
    Note

    Initial Criteria Required for Certain Reviews

    Review patients under Initial Authorization Criteria when they have received less than six months of therapy, are restarting Adbry, or are new to the plan and stable on the requested medication.

    • Initial approval is authorized for six months.
    • Reauthorization is provided in 12-month intervals.
  5. IGA/PGA: Investigator's Global Assessment or Physician Global Assessment score is at least 3.≥3
  6. Age: Patient is at least 12 years of age.≥12 years
  7. Prescriber: Adbry is prescribed by a dermatologist, allergist, or immunologist.
  8. Prior topical therapy: The patient has a documented history of failure of a minimum 30-day supply of one eligible topical therapy, or a 14-day supply for topical corticosteroids, unless contraindicated or clinically significant adverse effects are experienced.30 days; 14 days for topical corticosteroids

    Eligible therapies are medium- or high-potency topical corticosteroids, a calcineurin inhibitor, crisaborole, or ruxolitinib. Document the drug, date, and duration of the trial.

  9. Non-duplication: The patient is not receiving Adbry in combination with another biologic drug or a targeted synthetic oral small molecule drug.
  10. Prescriber:
    Adbry is prescribed by a dermatologist, allergist, or immunologist.
  11. Beneficial clinical response: Compared with baseline, the patient has experienced improvement in at least one of the following: estimated body surface area affected by atopic dermatitis, erythema, induration or thickness, scale of affected areas, or reduction in the use of other topical or systemic therapies.Improvement from baseline in ≥1 measure
  12. Symptom improvement: Compared with baseline, the patient has experienced improvement in at least one symptom of atopic dermatitis, such as pruritus, xerosis, crusting, or lichenification.Improvement from baseline in ≥1 symptom
  13. Non-duplication: The patient is not receiving Adbry in combination with another biologic drug or a targeted synthetic oral small molecule drug.